AOD-9604 vs Tirzepatide
A modified fragment of human growth hormone that targets fat cells for breakdown without affecting blood sugar or muscle growth—your metabolism's precision tool.
The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
AOD-9604
300–400 mcg
Tirzepatide
5–10 mg
Frequency
AOD-9604
Once daily
Tirzepatide
Once weekly
Administration
AOD-9604
Subcutaneous injection
Tirzepatide
Subcutaneous injection
Cycle length
AOD-9604
8-12 weeks
Tirzepatide
Ongoing/indefinite
Onset speed
AOD-9604
Gradual (3-4 weeks)
Tirzepatide
Moderate (1-2 weeks)
Evidence level
AOD-9604
Moderate human trials (Phase 1-2)
Tirzepatide
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Fat Targeting
Safety Profile
Joint Support
Weight Loss
Appetite Control
Blood Sugar Control
Compound specifications
AOD-9604
Molecular formula
C78H123N23O23S2
Molecular weight
1815.1 g/mol
Half-life
~3-4 minutes (plasma)
Bioavailability
High (subcutaneous)
CAS number
221231-10-3
Tirzepatide
Molecular formula
C225H348N48O68
Molecular weight
4813.45 g/mol
Half-life
Approximately 5 days (120 hours)
Bioavailability
~80% (subcutaneous)
CAS number
2023788-19-2
Dosing compared
AOD-9604
Subcutaneous
250 mcg
Once daily · 2-4 weeks
AOD9604 is a research peptide and not an approved medicine. Doses around 250 mcg under the skin are a common starting point in practice. In a human trial the most effective amount was about 1 mg per day. [1][5]
300-400 mcg
Once daily · 8-12 weeks
A commonly used daily amount in practice. The largest human study found benefit up to about 1 mg/day with no extra gain from higher doses. [1][5]
500 mcg
Once daily · 8-12 weeks
A higher amount sometimes used in practice. Going above roughly 1 mg/day did not improve results in the human trial. [1][5]
Tirzepatide
Subcutaneous injection
First 4 weeks
2.5 mg
Once weekly · First 4 weeks
FDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.
Increase by 2.5 mg after at least 4 weeks at each dose
5-10 mg
Once weekly · Increase by 2.5 mg after at least 4 weeks at each dose
Per FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].
Ongoing maintenance
12.5-15 mg
Once weekly · Ongoing maintenance
15 mg is the maximum FDA-labeled dose [5]. SURMOUNT-1 used up to 15 mg weekly for obesity [1].
Best suited for
AOD-9604
Targeted Fat Loss
AOD-9604 shines when you want to target stubborn fat deposits. It works by mimicking how growth hormone breaks down fat, but without the side effects of actual HGH. Think of it as a smart missile that targets fat cells specifically.
Body Recomposition
Perfect for those who want to lose fat while maintaining muscle. Unlike many fat loss compounds, AOD-9604 doesn't affect muscle tissue or mess with your blood sugar levels—it's laser-focused on fat metabolism.
Metabolic Enhancement
Ideal for boosting your metabolism naturally. AOD-9604 increases fat oxidation (your body's ability to burn fat for fuel) without the jittery stimulant effects of caffeine or other thermogenics.
Joint Health Support
Emerging research shows AOD-9604 may help repair cartilage and support joint health. Studies in osteoarthritis models show it can reduce cartilage damage, making it a dual-purpose peptide for active individuals.
Metabolically Safe Fat Loss
Unlike many weight loss compounds, AOD-9604 doesn't raise blood sugar, doesn't affect insulin, and doesn't stimulate cell growth. It's one of the gentlest approaches to enhancing fat metabolism available.
Tirzepatide
People Who Want Maximum Weight Loss Results
If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close [1].
Those Who Haven't Succeeded with Semaglutide
Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss [2][9].
People with Type 2 Diabetes Needing Aggressive Control
Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health [2].
Individuals Looking to Transform Their Relationship with Food
Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you [11].
Side effects
AOD-9604
Common
- Injection site reactions
- Mild headache
- Flushing or warmth
Uncommon
- Fatigue
- Dizziness
Serious
- Allergic reaction
Tirzepatide
Common
- Nausea
- Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Thinning (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Safety & evidence
AOD-9604
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved
Safety overview
AOD-9604 has been studied in multiple human clinical trials involving thousands of participants. The safety profile is notably clean—it doesn't affect blood sugar, insulin levels, or cause the typical side effects of growth hormone. Phase 2 trials showed it was well-tolerated even at doses higher than typically used. The most common side effects are mild and injection-site related.
Contraindications
- Pregnancy or breastfeeding
- Active cancer or history of cancer
- Known allergy to growth hormone-derived peptides
- Children and adolescents
Tirzepatide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. [1][2][3] The FDA approved it after thorough safety review. [5][6] While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. [5][6] Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes. [16]
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) [6]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [6]
- History of serious allergic reaction to tirzepatide [6] or any GLP-1/GIP medication
Which is right for you?
Choose AOD-9604 if...
- Fat loss
- Body composition improvement
- Metabolic support
- Joint health support
Choose Tirzepatide if...
- Maximum weight loss results
- Long-term obesity management
- Type 2 diabetes control
- Metabolic health improvement